You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Plant-Derived Estrogens and Cell Proliferation

    SBC: BIONOVO, INC.            Topic: NCCAM

    DESCRIPTION (provided by applicant): Menopause is associated with about a 10-15 pound weight gain and a redistribution of fat to the abdomen. The increase in abdominal fat, also known as visceral fat is known to produce cytokines that cause inflammation which can lead to the metabolic syndrome. The metabolic syndrome represents a major public health burden because it increases the risk of cardiova ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Novel RTL treatment to promote brain repair and cognitive recovery following meth

    SBC: VIROGENOMICS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Methamphetamine (MA) dependence is associated with neuropsychiatric side effects that make the addiction extremely challenging to treat. Patients seeking treatment experience ongoing impairments in cognition, mood, and motivation. Currently, there are no FDA-approved pharmacotherapies for MA dependence. The goal of this proof-of-concept research project is test ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Development of monoclonal catalytic antibodies for HIV immunotherapy

    SBC: COVALENT IMMUNOLOGY PRODUCTS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): We have raised murine monoclonal antibodies (MAbs) to a conserved region of the CD4 binding site of gp120 (CD4bs) that neutralize genetically diverse HIV strains. The MAbs have a novel mechanism of action. They hydrolyze multiple molecules of gp120, thereby imparting MAb increased biological efficacy. About 10% of HIV infected subjects develop resistance to cur ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Improve Wound Healing with HIF-CA5 DNA Vector and Electroporation

    SBC: CANTON BIOTECHNOLOGIES, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Therapy to Improve Wound Healing with DNA Expression Vector for HIF 11 and Electroporation Impaired wound healing is a tremendous problem for individuals with diabetes. Patients with diabetes are at risk for developing foot ulcers. These non-healing ulcerations on the foot are disabling, and their progression leads to amputation of the lower extremity. Diabetes ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Allergen???Fc-gamma1 proteins to treat food allergy

    SBC: TUNITAS THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop and commercialize a novel approach for allergen specific immunotherapy as treatment for severe food allergy. Food allergy affects about 3.5% of the US population and 6% to 8% of young children. It is clearly on the rise. Peanut allergy, which affects around 1% of the population, is among the most severe food allergies, r ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Technology Transfer of the ATLAS and ATHENA Programs

    SBC: Odyssey Science Innovations, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): Over 7.5 million high school students participate in high school sports programs and an additional 2 million students join these athletic teams each year. Adolescent athletes are at risk for using performance enhancing drugs, such as anabolic steroids, unregulated sport supplements, and illicit drugs and alcohol. Unfortunately, few evidence-based substance abus ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Noninvasive, Optoacoustic Monitoring of Cerebral Circulation in Preterm Neonates

    SBC: NONINVASIX INC            Topic: NICHD

    DESCRIPTION (provided by applicant): Premature, very-low-birth-weight (VLBW; d1500 g) and low-birth-weight (LBW; 1500-2499 g) infants are at increased risk for long-term encephalopathy. 25-50% of the 63,000 VLBW infants born annually in the U.S. have majorlong-term cognitive or neurobehavioral deficits. Postnatal cerebral ischemia appears to play an important role in long-term cognitive sequelae. ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Multi-Functional Nanotube-Based Sensor Array for Detecting Blood Coagulation Defects

    SBC: INNOSENSE CORPORATION            Topic: DHA19A001

    Defense Health Agency (DHA) is seeking a multi-functional diagnostic to determine blood coagulopathy in real time at point-of-care (POC). Blood coagulopathy, resulting in uncontrolled bleeding, is implicated in 80% of operating room deaths and 50% of trau

    STTR Phase I 2019 Department of DefenseDefense Health Agency
  9. Rapid, noninvasive diagnosis and monitoring of shock

    SBC: NONINVASIX INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Assessment and management of circulatory shock in critically ill patients requires rapid measurement of two critical variables: mixed venous oxyhemoglobin saturation (venous SO2) and total blood hemoglobin concentration [Hgb] to identify insufficient oxygen delivery and anemia and to determine the need for therapy with fluids, inotropic or vasodilator drugs or ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Carbidopa, an iron chelator and an ABCG2 inducer, for treatment of gouty arthritis

    SBC: South Plains Biotechnology, Inc            Topic: NIAMS

    Our goal is to evaluate the efficacy of the FDA approved drug Carbidopa for the treatment of gouty arthritis in mouse modelsCarbidopa is used to treat Parkinson s diseasebut always in combination of L DOPAnever alone by itselfGouty arthritis is caused by deposition of monosodium urateMSUcrystals in jointsinitiating inflammation and arthritisInterestinglygout is not always directly related to incre ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government